Endocrinology
Partner With Us
Advertisement
Conexiant chevron_right Endocrinology chevron_right Finerenone Lowers Risk of New-Onset Diabetes in Heart Failure
From the Journals

Finerenone Lowers Risk of New-Onset Diabetes in Heart Failure

Oral finerenone reduced the hazard of new-onset diabetes by 24% in heart failure patients, offering a potential clinical benefit.

Conexiant
article Full Article subject Summary summarize Notecard
  1. Finerenone, a mineralocorticoid receptor antagonist, significantly reduced new-onset diabetes incidence in heart failure patients.
  2. The reduction represented a meaningful clinical benefit, supporting finerenone as a treatment option for heart failure.
  3. Effects of finerenone were consistent across heart failure severity subgroups and additive with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.
  4. The study compared the effects of finerenone with other mineralocorticoid receptor antagonists, such as eplerenone.
  5. The sodium-glucose co-transporter 2 inhibitor dapagliflozin has also been shown to reduce diabetes incidence in heart failure and reduced ejection fraction.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.